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Background: Attempts to enrich or identify DNA with cytosine methylation have been commonly carried out
using anti-5-methylcytosine or anti-MBD2 (methyl-CpG binding domain protein 2) antibody in immunoprecipitation
(IP) assays. However, a careful and systematic control experiment to examine the sensitivity and specificity of this
approach has not been reported. It is of critical importance to understand the potential pitfalls of this approach and
to avoid potential misinterpretation of findings.
Findings: We found that increased concentration of antibody used in the assay increased the amount of overall
DNA captured as expected. The increased number of methylated cytosines in/on the DNA fragment also increased
the amount of DNA captured by the antibody. Importantly, the antibody can bind to some fully unmethylated DNA
fragments, even when fully methylated DNA is present in the same experiment.
Conclusion: The sensitivity of anti-5-methylcytosine antibody and anti-MBD2 antibody/MBD2 binding varies with
the number of methylated cytosines on the DNA target. The specificity of these antibodies can also vary for different
DNA target sequences. DNA fragments with fewer CpG sites may not bind to these antibodies even when all are
methylated while DNA fragments with more CpG sites may bind to the antibodies when only some of these sites
are methylated. More importantly, binding of DNA to these antibodies does not always indicate the presence of
DNA methylation. It is clear that false positive and false negative findings can be easily reached even though it
does not nullify these convenient and simple methods completely. Great caution should be taken for the interpretation
of IP results using these antibodies and rigorous confirmation by sodium bisulfite sequencing is essential.
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Study design
The feasibility of using antibodies in immunoprecipita-
tion (IP) to pull down DNA harboring 5-methylcytosine
is evaluated in this study. DNA fragments from a plas-
mid with different numbers of CpG sites that can be
methylated in vitro to different levels are used as targets
in the IP. Plasmid DNA fragments with a single CpG
methylation pattern and a mixture of plasmid DNA with
different CpG methylation patterns were tested in the IP
experiments. After IP, the precipitated DNA is analyzed
quantitatively and qualitatively to determine the sensitiv-
ity and specificity of the assay.* Correspondence: hsieh_c@ccnt.hsc.usc.edu
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Plasmid DNA from pCLH22 was methylated in vitro
with SssI, HhaI, and HpaII methylases individually accord-
ing to the manufacturer’s instruction (NEB). The unmethy-
lated and methylated plasmid DNA were digested with
restriction enzyme MseI, followed by phenol/chloroform
extraction and ethanol precipitation, and resuspended in
TE (10 mM Tris pH 8.0, 1 mM EDTA) to generate DNA
fragments harboring different numbers of methylated CpG
sites (Table 1). IP using anti-5-methylcytosine (anti-5-me-
thyl-C) monoclonal antibody (Diagenode) was carried out
with different concentrations of the antibody and various
target DNAs as described previously [1]. IP using anti-
MBD2 antibody and MBD2 protein was carried out
according to the manufacture’s instruction (Methyl-
Collector kit, Active Motif ). DNA pulled down by the
antibody either directly (anti-5-methyl-C) or indirectlyntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Target DNA fragment sizes and number of sites











412 LTR1 1 0 21
LTR3 1 0 21
666 Luc1 3 4 37
185 Luc2 0 1 7
428 Luc3 1 2 30
1720 Hyg5 10 10 143
365 PBR 1 2 23
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tation by quantitative real-time PCR (q-PCR) using six to
eight TagMan probe and primer sets specific for various
regions of the plasmid [2,3]. The percent pull down is
calculated by dividing the DNA in the specific experiment
after IP by the total chromatin fraction before the IP. A
qualitative analysis by sodium bisulfite sequencing [4] of
the DNA recovered after IP was also carried out to deter-
mine the methylation pattern on the DNA fragments that
were precipitated by the antibody.
Results
Percent pull down increases with antibody concentration
Three different concentrations of anti-5-methyl-C anti-
body, 2.5, 5, and 10 ng/ul, were used in each pull down
experiment of 30 ul volume with 100 ng of MseI digested
pCLH22 (Figure 1A) target DNA methylated at all CpG
sites. Experiments using MseI digested fully unmethylated
pCLH22 as target DNA were carried out as negative
controls. Experiments with no antibody was done in
parallel for all configurations as controls for binding of
the target DNA to the protein G-sepharose beads.
When 2.5 ng/ul concentration of antibody was used,
from 0.3% (LTR1) to 3.5% (Hyg5) of the fully methylated
pCLH22 DNA fragments were pulled down (Figure 1B).
At this antibody concentration, approximately 0.1% to
0.5% of the unmethylated pCLH22 DNA fragments were
pulled down from the six regions examined (Figure 1C).
When 5 ng/ul concentration of antibody was used, the
percent pull down was almost 1% for the LTR1 region and
at 10.8% for Hyg5 region of the fully methylated pCLH22
(Figure 1B), while the unmethylated pCLH22 fragments
were pulled down at the level of up to 0.7% (Figure 1C).
Percent pull down increased to 1.9% for the LTR1 region
and 24.8% for the Hyg5 region when antibody con-
centration was 10 ng/ul for fully methylated pCLH22
(Figure 1B), and was up to 2% for the unmethylated
pCLH22 (Figure 1C). It is clear that the amount of DNA
precipitated increases with increasing concentration of
antibody for all DNA regions, except Luc2, examined
for methylated DNA. While the same trend is alsoobserved for unmemthylated DNA targets, the increases
are much less notable and remain to be at what can be
considered background noise level. Much more fully
methylated DNA fragments with 37 and 143 CpG sites
than totally unmethylated same DNA fragments (quan-
titated by qPCR of Luc1 and Hyg5 regions) were clearly
and consistently pulled down in all the experiments. It
is also noted that the DNA fragment harboring the
Luc3 amplicon was pulled down by the beads along in
the no antibody control at a higher rate when it is
unmethylated (Figure 1C). These observation suggest
that while more than seven methylated CpG sites has
good potential to be distinguished from fully unmethy-
lated DNA using the anti-5-methyl-C antibody, many
more methylated CpG sites on the DNA fragment may
be needed to be unequivocally identified all the time.
Percent pull down increases with number of CpG sites in
the DNA fragment
Different MseI digested DNA fragments from pCLH22
harbor different numbers of CpG sites (Table 1). Also,
SssI, HhaI, and HpaII methylases methylate different
numbers of CpG sites on the same DNA fragment based
on their recognition sequences (Table 1). Three concen-
trations of anti-5-methyl-C antibody, 2.5, 5, and 10 ng/ul,
were used in each pull down experiment of 30 ul volume
with 100 ng of MseI digested pCLH22 target DNA that
was methylated at all CpG sites, at only HhaI sites, and at
only HpaII sites. Fully unmethylated pCLH22 as target
DNA was used as a negative experimental control.
Experiments with no antibody are done in parallel to
determine the background due to the beads used in the
assay. Nearly 25% of the fully methylated DNA fragment
was detected by the Hyg5 probe/primer set as pulled
down by the anti-5-methyl-C antibody at 10 ng/ul con-
centration (Figure 2A). This DNA fragment is 1720 bp
in length and has 143 CpG sites (Table 1). In the same
IP experiment, less than 0.4% of the DNA fragment was
pulled down as detected by the Luc2 probe/primer set
(Figure 2A), and this DNA fragment is 185 bp in length
with seven CpG sites (Table 1). About 1.5% of the
1720 bp DNA fragment was pulled down by the anti-
body when 10 of the 143 CpG sites on the fragment
were methylated by the HhaI methylase (Figure 2A), in-
dicating that the long length of the DNA does not favor
the capability of antibody binding to the fragment.
While DNA fragments with 21 and 30 methylated CpG
sites (assayed by LTR1, LTR2, and Luc3) were pulled down
at around 2% level, the same DNA fragments were also
pulled down at a similar or even higher level when they
are unmethylated (Figure 2A). Similar results were found
with all three concentrations of antibody (Figures. 2A, B,
and data not shown). The 5-methyl-C antibody only
consistently pulled down more methylated DNA than
Figure 1 Increase in anti-5-methyl-C antibody concentration increases the efficiency of IP. qPCR was used to quantitate various regions of
the fully methylated target DNA to determine the percentage of pull down, calculated by dividing the amount of DNA after IP by the amount of
input DNA, with different concentrations of the antibody for the IP. A) A schematic diagram of MseI restriction sites on pCLH22. MseI restriction
sites are as marked by short lines on the circle and the nucleotide positions of DNA fragments examined are as numbered. The solid arrows indicate the
locations of the qPCR amplicons with the number of CpG sites in the box under the name of each probe/primer set. The hollow arrows mark the
regions examined by sodium bisulfite sequencing. B) Percentage of IP using different concentrations of antibody and no antibody with fully methylated
pCLH22 as target. C) Percentage of IP using different concentrations of antibody and no antibody with entirely unmethylated pCLH22 as target.
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sites are present on the DNA fragment (Figures 2A and
B), reflecting the limitation of the antibody in distinguish-
ing methylated and unmethylated DNA. Regardless of theantibody concentration used, it appears that the amount
of DNA fragment pulled down by the antibody increases
with increasing numbers of methylated CpG sites on the
fragment (Figure 2D).
Figure 2 Percent pull down by anti-5-methyl-C antibody increases with increasing number of methylated CpG sites on the target DNA
fragment. A) Average % pull down from multiple experiments using 10 ng/ul of antibody in the IP assays with differently methylated target
DNA. Six regions quantitated by the TaqMan assay in five different MseI restriction fragments are presented. The number of CpG sites on each
MseI restriction fragment and target DNA methylated with HhaI, HpaII, or SssI methylase harbor different numbers of methylated CpG sites as
indicated in Table 1. B) 5 ng/ul of antibody was used in the IP assays. C) Parallel IP assays of A) and B) with no antibody as negative controls. In
these three illustrations, the Y-axis is % pull down. D) Plot of methylated CpG sites on the DNA fragment (X-axis) and the % pull down (Y-axis)
from the IP assays using 10 ng/ul antibody.
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In theory, only molecules with cytosine methylation
should be pulled down by the antibody if the antibody is
specific. The specificity of the anti-5-methyl-C antibody
was examined by mixing differently methylated DNA
for the IP. Equal amounts of fully methylated, HhaI-
methylated, HpaII-methylated, and fully unmethylated
pCLH22 DNA after digesting with MseI restriction en-
zymes were mixed for the IP using anti-5-methyl-C anti-
body at 5 ng/ul concentration. The methylation patterns
in three different regions of the DNA were determined
by the sodium bisulfite sequencing method to identify
whether methylation exists at the HhaI only, HpaII only,
or all CpG sites on the DNA pulled down by the antibody.
Region 1 studied by the sodium bisulfite sequencing
method harbors none of the two HhaI sites, two of the
11 HpaII, and 11 of the 54 CpG sites on a 1917 bp MseI
fragment. Of 57 molecules sequenced from this region,
14 had no detectable CpG methylation (24.6%) that in-
clude unmethylated and HhaI-methylated input DNA
since there are no HhaI sites within the PCR amplicon
for sodium bisulfite sequencing (Table 2). Molecules
methylated at HpaII sites and at all CpG sites account
for 21.1% and 54.4% of the molecules sequenced from
region 1, respectively (Table 2). Amplicon for region 2
contains both HpaII sites and 11 of the 12 CpG sites of
the 283 bp MseI fragment, which has no HhaI sites,
where it resides (Table 2). While 50% of the DNA from
this 283 bp MseI fragment in the input has no CpG
methylation and should not be pulled down by the anti-
body, 11.3% of the molecules sequenced from this region
had no CpG methylation (Table 2). A total of 88.7% of
the molecules sequenced was HpaII-methylated (4.8%)Table 2 Summary of number of molecules identified with diff





1 Unmethylated 0 0
Hha-methylated 2 0
HpaII-methylated 11 2
Fully methylated 54 11
2 Unmethylated 0 0
Hha-methylated 0 0
HpaII-methylated 2 1
Fully methylated 12 11
3 unmethylated 0 0
Hha-methylated 3 2
HpaII-methylated 3 1
Fully methylated 23 17or fully methylated (Table 2). Region 3 amplicon includes
two of the three HhaI sites, one of the three HpaII sites,
17 of the 23 CpG sites on a 1088 bp MseI fragment
(Table 2). Among the molecules sequenced from this re-
gion, 10.3% was unmethylated, 4.4% was HhaI-methyalted,
8.8% was HpaII-methyalted, and 76.5% was fully methyl-
ated (Table 2). Although these sodium bisulfite sequencing
assays are not considered quantitative, it is clear that
unmethylated DNA is pulled down by the antibody at a
level that should not be dismissed or neglected. It is note-
worthy that DNA fragments with no methylation are de-
tected in these assays at a frequency similar to or no lower
than DNA fragments with two or three methylated sites.
This finding is consistent with the results described above
that anti-5-methyl-C antibody is not reliable in distinguish
fully unmethylated DNA and DNA fragments with fewer
than 10 methylated CpG sites.
Anti-MBD2 antibody pull down also increases with the
number of CpG sites on the DNA fragment
Anti-MBD2 antibody is also commonly used to iden-
tify DNA with CpG methylation indirectly through
the MBD2 protein. MseI restriction enzyme digested
unmethylated, HhaI-methylated, HpaII-methylated, and
fully methylated pCLH22 DNA was individually used as
targets for IP with anti-MBD2 antibody and MBD2
protein to assess the feasibility of this assay. The per-
centage pull down of unmethylated DNA (Figure 3),
much less than 0.5%, was clearly at the same level as
the control assay without the antibody (data not
shown) indicating a very low background of the IP
using this antibody. However, the level of pull down of
HhaI-methylated and the HpaII-methylated DNAerent methylation patterns in IP assays using 5-methyl-C
# of molecules detected in % of total















Figure 3 Percent pull down by anti-MBD2 antibody increases with increasing number of methylated CpG sites on the target DNA
fragment. The Y-axis indicates the % pull down from IP assays of fully methylated target DNA.
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were also much less than 0.5% (Figure 3). The fully
methylated DNA fragments were pulled down at a level
from 0.1% for the fragments with seven methylated sites
(i.e. Luc2) to nearly 20% for fragments with 143
methyalted sites (i.e. Hyg5) (Figure 3). These findings
indicate that the capability of anti-MBD2 to pull down
methylated DNA increases with the number of methyl-
ated CpG sites on the DNA fragment and the DNA can
be reliably pulled down by the antibody when it has
more than 20 methylated sites. It should be noted that
we have no information on the feasibility or reliability
for pulling down DNA with less than 21 and more than
10 methylated CpG sites.Table 3 Summary of number of molecules identified with diff





1 unmethylated 0 0
Hha-methylated 2 0
HpaII-methylated 11 2
Fully methylated 54 11
2 unmethylated 0 0
Hha-methylated 0 0
HpaII-methylated 2 1
Fully methylated 12 11
3 unmethylated 0 0
Hha-methylated 3 2
HpaII-methylated 3 1
Fully methylated 23 17Specificity of anti-MBD2 may be affected by the nature of
DNA fragment in addition to the number of methylation
sites on the DNA
The same experiment of mixing differently methylated
and unmethyalted target DNA in the IP followed by
sodium bisulfite sequencing as described above using
the anti-MBD2 and MBD2 protein was carried out to
evaluate the specificity of the antibody. For regions 1
and 2, it appears that the antibody is much more specific
for fully methylated DNA (93.9% and 82.4%, respectively)
than unmethylated, HhaI-methylated, or HpaII-methylated
DNA (Table 3). To our surprise, most of the molecules
sequenced (80.4%) from region 3 were fully unmethy-
lated (Table 3). As described above, all DNA regionserent methylation patterns in IP assays using anti-MBD2
# of molecules detected % of total
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Okitsu and Hsieh BMC Research Notes  (2015) 8:102 Page 7 of 7examined by qPCR showed very low IP pull down of
unmethylated targets. Since this DNA fragment was not
assayed in the qPCR quantitative analysis, region 3 was
amplified from sodium bisulfite treated DNA from two
additional IP of mixed DNA target. Again, unmethy-
lated DNA was preferentially pulled down by the anti-
body (Exp. 3 and Exp. 4 in Table 3). To ensure that this
region can be amplified after sodium bisulfite treatment
when the CpG methylation is present, the DNA pulled
down from IP of MseI digested fully methylated pCLH
22 DNA was sequenced by the sodium bisulfite method.
All 16 molecules sequenced from this control experi-
ment in duplicate were fully methylated at CpG sites. It
is unclear why anti-MBD2 antibody performs poorly in
pulling down the 1088 bp MseI fragment within which
the region 3 resides. The length of the DNA fragment
does not appear to be an issue for this assay since region
1 assayed is on a DNA fragment of 1917 bp and region
2 is on a DNA fragment of 283 bp. Also, the number of
methylated CpG sites does not seem to play a role in
this phenomena since DNA fragment harbors region 2
has only 12 CpG sites. This 1088 bp fragment contains
the EBV oriP region containing many repeat sequences,
and this feature and the DNA sequence may cause the
favorable binding of MBD2 protein and/or the antibody
to this DNA fragment when it is unmethylated. The
findings here indicate that while anti-MBD2 can pull
down DNA fragments with more than 12 methylated
CpG sites pretty reliably through MBD2 binding, it may
be affected by DNA sequence or conformation.
Conclusions
Both anti-5-methyl-C and anti-MBD2 antibodies can
pull down DNA fragments with multiple methylated
CpG sites. The capability of both of these antibodies to
pull down methylated DNA increases with the number
of CpG sites on the DNA fragment. Anti-5-methyl-C
antibody can pull down unmethylated DNA at a non-
negligible level around 2%, and it can pull down DNA
fragments with more than 30 CpG sites reliably and
consistently. While anti-MBD2 appears to have good
specificity for pulling down highly methylated DNA with
12 or more CpG sites indirectly through the binding of
MBD2 protein to the DNA, it may be affected by DNA
sequence or conformation. Fully unmethylated DNA can
be captured by both antibodies and create false positive
findings. Also, some DNA fragments may bind to the
beads used in the assay and create false positive finding.
These types of false positive findings without rigorous
confirmation had led to the report of 5-methyl-C pres-
ence in human mitochondrial DNA [5], which has been
conclusively ruled out [6]. Also, DNA harboring less
than 10 methylated sites can easily be missed by both
antibodies and false negative findings can be derived.Parallel experiments using the two antibodies individu-
ally in the assay may provide one level of confirmation
since the two antibodies may complement each other to
reduce false positives and false negatives. In conclusion,
both anti-5-methyl-C and anti-MBD2 antibodies can be
used to identify DNA with multiple methylated CpG
sites, preferably more than 10 sites, but great caution
should be taken in interpreting the findings. In this
study, we only tested each antibody from a single source,
careful testing of antibodies from each and different ven-
dors should be carried out to ensure the experimental
results are correctly interpreted. Careful confirmation
using sodium bisulfite sequencing method should be
made before reaching a final conclusion.
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